GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Forward PE Ratio

Gala Pharmaceutical (Gala Pharmaceutical) Forward PE Ratio : 0.00 (As of May. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Forward PE Ratio?

Gala Pharmaceutical's Forward PE Ratio for today is 0.00.

Gala Pharmaceutical's PE Ratio without NRI for today is 0.00.

Gala Pharmaceutical's PE Ratio for today is 0.00.


Gala Pharmaceutical Forward PE Ratio Historical Data

The historical data trend for Gala Pharmaceutical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Forward PE Ratio Chart

Gala Pharmaceutical Annual Data
Trend
Forward PE Ratio

Gala Pharmaceutical Quarterly Data
Forward PE Ratio

Competitive Comparison of Gala Pharmaceutical's Forward PE Ratio

For the Biotechnology subindustry, Gala Pharmaceutical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gala Pharmaceutical's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gala Pharmaceutical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Gala Pharmaceutical's Forward PE Ratio falls into.



Gala Pharmaceutical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Gala Pharmaceutical  (OTCPK:GLPH) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Gala Pharmaceutical Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.